<DOC>
	<DOCNO>NCT01935804</DOCNO>
	<brief_summary>The study test whether pioglitazone ( PIO ) compare metformin ( MET ) affect bone health include bone mineral density , bone turnover marker , osteocyte biomarker patient type 2 diabetes ( T2DM ) .</brief_summary>
	<brief_title>Effect Pioglitazone Versus Metformin Bone Health Postmenopausal Women With Type 2 Diabetes</brief_title>
	<detailed_description>Women T2DM exhibit normal high bone mineral density ( BMD ) age , approximately twice overall risk bone fragility compare nondiabetic subject . Known apparent association T2DM risk bone fragility , examine effect commonly use oral antidiabetic agent ; MET thiazolidinediones ( TZDs ; example rosiglitazone [ ROS ] PIO ) , BMD and/or bone turnover great clinical relevance diabetic patient treat physician . Recent clinical trial , show woman treat ROS high risk bone fragility self-reported adverse event . Similarly , woman long-term treatment PIO T2DM experience high incidence distal extremity fracture . TZDs agonists nuclear transcription factor peroxisome proliferator- activate receptor-γ ( PPAR-γ ) increase insulin sensitivity improve glycemic control T2DM . PPAR ( γ ) act also molecular factor favour adipogenesis osteoblastogenesis mesenchymal stem cell . The latter suggest potential mechanism effect TZDs bone among others . In human , TZDs decrease BMD increase bone fragility risk . This study test whether pioglitazone compare MET ( commonly use treatment T2DM Saudi Arabia country ) affect bone health include bone mineral density , bone turnover marker , osteocyte biomarker patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>BMD Tscore great 2.5 total hip , femoral neck , lumbar spine ; No prior antidiabetic therapy ; Drugnaïve glycosylated hemoglobin A1c ( HbA1c ) ≥ 7.0 ≤ 10.0 % . 53.2 mmol/mol 88.2 mmol/mol ) ; Bodymass index 40 Kg/m2 less ; Stable body weight least 4 month . Type 1 diabetes mellitus ( presence GAD auto antibody ) ; History diabetes uncontrolled hypertension ; Treatment antidiabetic agent include TZDs ; Chronic diseases know affect bone ; Previous treatment estrogen medication know affect bone ; Creatinine clearance le 60 ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pioglitazone</keyword>
	<keyword>metformin</keyword>
	<keyword>hyperglycemic agent</keyword>
	<keyword>physiological effect drug</keyword>
	<keyword>bone health</keyword>
</DOC>